Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Organ-on-chip platforms for nanoparticle toxicity and efficacy assessment: Advancing beyond traditional in vitro and in vivo models

Sampaio AR., Maia RF., Ciardulli MC., Santos HA., Sarmento B.

Narrative Review on Face & Skin, Hip, published in Mater Today Bio (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Mater Today Bio (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40688675
PMCID
PMC12274808
DOI
10.1016/j.mtbio.2025.102053
Citations
7

Abstract (original English)

Nanoparticles (NPs) have unique properties, such as their high surface-to-volume ratio, nanoscale size, and functionalization potential, make them promising for a variety of biomedical applications, including drug delivery, diagnostics, and targeted therapy. With rapid progress in NPs research, increasing efforts are being made to develop new technologies for in vitro modeling and analysis of the efficacy and safety of nanotherapeutics in human physiological systems. Organ-on-chip (OoC) platforms are a cutting-edge alternative to traditional in vitro and in vivo models that provide a ground-breaking way to evaluate the toxicity and therapeutic efficacy of NPs. This review explores the advancements and achievements in OoC technology, focusing on explore the recent advances in healthy and diseases models and its potential to enhance NPs safety and efficacy. By simulating human biological systems, OoC help identify negative effects and mechanisms of action, reducing preclinical research failures and promoting targeted treatments. These platforms can cut down on drug development time and costs, making them invaluable for personalized medicine. However, challenges such as scalability and regulatory hurdles must be addressed before OoC can become a standard in NPs research and drug development. This review offers a critical and current summary of recent developments in OoC models for

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research